The Clinical Proteomic Tumor Analysis Consortium (CPTAC) analyzes cancer biospecimens by mass spectrometry, characterizing and quantifying their constituent proteins, or proteome. Proteomic analysis for each CPTAC study is carried out independently by Proteomic Characterization Centers (PCCs) using a variety of protein fractionation techniques, instrumentation, and workflows. Mass spectrometry and...

This dataset contains summary data visualizations and clinical data from a broad sampling of 566 lung adenocarcinomas from 566 patients. The data was gathered as part of the PanCancer Atlas initiative, which aims to answer big, overarching questions about cancer by examining the full set of tumors characterized in the robust TCGA dataset. The clinical data includes mutation count, information about...

This dataset contains summary data visualizations and clinical data from a broad sampling of 1,661 samples of across multiple cancer types showing tumor mutational load and survival following immunotherapy from 1,661 patients. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK),...

This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...

This dataset contains summary data visualizations and clinical data from a broad sampling of tropomyosin receptor kinase (TRK) fusion tumors. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), information about mutated genes, patient demographics, and modality. The data set also...

This dataset contains summary data visualizations and clinical data from a broad 183 samples of thoracic tumors from 77 patients. The data was generated by the Charles Rudin Lab, utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, patient demographics,...

TCGA Lung Adenocarcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 586 carcinomas from 584 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information about...

This dataset contains the summary data visualizations and clinical data of IMPACT sequencing of 229 cell-free DNA (cfDNA) and associated tumor samples with matched normal from 118 patients. Clinical data includes: Cancer Type, Number of Samples Per Patient, Mutation Count, Fraction Genome Altered, Sex, Primary/Metastasis Sample Type, Collaboration Id, Gene Panel, Oncotree Code, Tumor/cfDNA Sample...

This dataset contains the summary data visualizations and clinical data from IMPACT sequencing of 240 NSCLC tumor/normal pairs treated at MSKCC with anti-PD-(L)1 based therapy from 240 patients. Clinical data includes: Cancer Type, Mutation Count, Fraction Genome Altered, Sex, Durable Clinical Benefit, FGA, Gene Panel, IRB, Lines of treatment, Mutation Rate, Oncotree Code, PD-L1 Score (%), Smoker,...

Summary from the GEO: "The purpose of this study was to identify gene targets differentially regulated by shRNA-mediated knockdown of the HSF1 transcription factor in the brain-metastatic lung adenocarcinoma cell line PC9-BrM3." Overall design from the GEO: "Samples were analyzed for differential gene expression in PC9-BrM3 cells transduced with shRNAs against NTC (non-target control) versus HSF1....